Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   HER2-Negative Breast Carcinoma Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Other: Medical Chart Review;   Other: Questionnaire Administration Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials